osteoclastogenesis

VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1).

Sciadopitysin may prevent the development of diabetic osteopathy, it exerts its therapeutic effects via upregulation of mitochondrial biogenesis.Sciadopitysin shows protective effects on antimycin A-induced toxicity in osteoblastic MC3T3-E1 cells, it may

4-IPP (4-Iodo-6-phenylpyrimidine) is an irreversible inhibitor of macrophage migration inhibitory factor (MIF).

NDMC101 is an inhibitor of dipeptidyl peptidase-IV activity in human T cells and exhibits immunomodulatory effects. It also acts as a novel inhibitor of NFATc1 and NF-κB activity.

WAY-325398 is a furan derivatives. WAY-325398 inhibits osteoclast formation, inhibition rate is 14.11% at 10 μM.

Gossypin has antidiabetic, antioxdiant, anticonvulsant, anti-allergic, antiinflammatory, antinociceptive, cytotoxic and antibacterial activities; it inhibits the NF-kappaB activation pathway, which may explain its role in the suppression of inflammation,

BCI hydrochloride ((E)-BCI hydrochloride) is a selective dual-specificity phosphatase 6 (DUSP6) inhibitor that inhibits RANKL-mediated osteoclastogenesis and attenuates oophorectomy-induced bone loss.BCI hydrochloride has anti-inflammatory activity, reduces reactive oxygen species (ROS) production, and partially reverses AE-induced bone loss. BCI hydrochloride has anti-inflammatory activity and can reduce reactive oxygen species (ROS) production, partially reverse AE-induced cytotoxicity, and increase ERK activity, which can be used to study inflammatory diseases.

3-(3-Hydroxyphenyl)propionic Acid (m-Hydroxyphenylpropionic acid) is one of the major metabolites of ingested caffeic acid.it inhibited osteoclastogenesis and bone osteoclastic resorptive activity.

(+)-Medicarpin, a pterocarpan, is an isoflavonoid compound derived from medicinal plant species such as Sophora japonica, Zollernia paraensis, Platymiscium yucatamun, Machaerium aristulatum, and Platymiscium floribundum. It potently inhibits osteoclastogenesis and facilitates bone healing and increased bone mass through osteoblast differentiation, mediated by the estrogen receptor (ER) β.

Latanoprost acid is a selective agonist of prostanoid receptors and inhibits RANKL-induced osteoclastogenesis and function through the inhibition of c-fos/NFATc1 pathway. Latanoprost acid can be used in studies about lowering pressure inside the eyes.

Sauristolactam inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation. Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus Chi

S24-14 serves as an effective anti-osteoporosis agent by inhibiting osteoclastogenesis, promoting osteoblast differentiation, and reducing bone resorption.

AS2690168 freebase is an orally active inhibitor of RANKL signaling, capable of suppressing RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.

ELP-004 is a TRPC channel inhibitor that blocks Ca2+ entry mediated by TRPC channels. It serves as an osteoclast inhibitor by preventing osteoclast differentiation. ELP-004 also hinders basal Ca2+ levels and the associated translocation of NFATc1 in inflammatory osteoclastogenesis. Additionally, it reduces bone erosion in mouse models of rheumatoid arthritis.

SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory properties. It inhibits RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclastogenesis in primary bone marrow-derived macrophages and suppresses the activation of MAPKs, Akt, and NF-κB pathways. Furthermore, SPA0355 enhances osteoblast differentiation by increasing alkaline phosphatase activity and mineralized nodule formation. It protects ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it a potential candidate for studying postmenopausal osteoporosis.

AS2690168 hydrochloride is an orally active inhibitor of RANKL signaling that can suppress RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.

PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.

Anti-osteoporosis agent-8 (Compound 4aa) is a RANKL inhibitor, capable of preventing RANKL-induced osteoclastogenesis and osteoclast differentiation, with an IC50 of 2.41 μM. Furthermore, Anti-osteoporosis agent-8 has been shown to mitigate bone loss in an ovariectomized (OVX) mouse model.

LSD1-IN-32 (compound 11e) is a potent inhibitor of LSD1, with an IC50 value of 0.99 µM. It effectively impedes RANKL-induced osteoclastogenesis, bone resorption, and F-actin ring formation, indicating its potential use in osteoporosis research.

Y2641, a tetrahydro β-carboline derivative, is an orally active dual inhibitor of RANKL and TNF-α, with Kd values of 3.984 μM and 18.59 μM respectively. It suppresses RANKL-induced osteoclastogenesis and exhibits anti-inflammatory and cartilage-protective properties. Y2641 is applicable in osteoarthritis research.

GL64 is a selective agonist of ADGRD1 with an EC50 of 3.98 μM. It shows low selectivity for the subtypes ADGRD2, ADGRG5, ADGRG6, CELSR1, CELSR2, CELSR3, and ADGRG4. GL64 activates ADGRD1 by mimicking the satchel sequence. It regulates osteoclast maturation through the cAMP-PKA-NFATC1 pathway. Both in vivo and in vitro, GL64 effectively inhibits osteoclastogenesis and prevents bone loss. This compound is suitable for research into osteoclast-related diseases.

SC 19220 is a prostaglandin E2 receptor EP1 antagonist.SC 19220 inhibits RANKL-induced osteoclastogenesis by inhibiting the RANK/RANKL signaling pathway in osteoclast precursors.

Halenaquinone is a phosphatidylinositol 3-kinase inhibitor. Halenaquinone specifically inhibits the secondary DNA binding of RAD51. Halenaquinone inhibits RANKL-induced osteoclastogenesis. Halenaquinone induces apoptosis in PC12 cells.

Ethyl gentisate (Ethyl 2,5-dihydroxybenzoate) acts as a dual regulator of cell differentiation, promoting osteoblast differentiation while inhibiting osteoclast differentiation. It enhances osteogenic differentiation and alkaline phosphatase activity in human mesenchymal stem cells (hMSCs), and suppresses RANKL-activated osteoclastogenesis in RAW264.7 cells.